zirconium Zr 89 crefmirlimab berdoxam
Sponsors
Leids Universitair Medisch Centrum (LUMC), ImaginAb, Inc., University Medical Center Groningen, Jonsson Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center
Conditions
GliomaLocally Advanced Solid TumorLung CancerMalignant Brain NeoplasmMelanomaMeningiomaMerkel Cell Carcinoma, UnspecifiedMetastatic Malignant Neoplasm in the Brain
Phase 1
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RecruitingNCT06650163
Start: 2024-12-05End: 2028-01-31Target: 20Updated: 2026-02-05
(ACTME) Adoptive TIL therapy with low-dose PEG-IFNa plus nivolumab in metastatic melanoma
Not yet recruitingCTIS2024-516125-31-02
Target: 58Updated: 2025-08-12
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
RecruitingNCT06863233
Start: 2025-03-03End: 2028-03-03Target: 5Updated: 2025-08-12
Phase 2
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
Active, not recruitingNCT05013099
Start: 2021-12-09End: 2025-07-31Updated: 2024-07-22
CD8 PET Imaging in Metastatic Solid Tumours
RecruitingNCT06534190
Start: 2025-03-11End: 2028-11-01Target: 30Updated: 2026-02-09